Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Double-blind, parallel group, placebo-controlled randomized trial.

Endothelial function and blood pressure were measured and fasting blood samples were taken at baseline and 8 weeks after administration of vitamin D.

What Was Measured

PubMed files the paper under topics including 25-Hydroxyvitamin D 2, Blood Pressure, Diabetes Mellitus, Type 2, Dietary Supplements, Endothelium, Vitamin D and Vitamin D Deficiency.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.